P-222: Glycemic outcomes in cystic fibrosis–related diabetes in youth: discordance between HbA1c and CGM metrics and limited evidence on diabetes technologies — a systematic review
P-222: Glykämische Outcomes bei zystischer Fibrose-assoziiertem Diabetes im Kindes- und Jugendalter: Diskrepanz zwischen HbA1c und CGM-Metriken und begrenzte Evidenz zu Diabetestechnologien – systematische Übersicht
Hormone Research in Paediatrics · 04.11.2026 · 99 (Supplement_4)
DOI: 10.1159/hrp/adaag020.280 ↗Auf einen Blick
Die systematische Übersicht fand nur wenige pädiatrische Studien zu CFRD. HbA1c veränderte sich unter CFTR-Modulatoren unterschiedlich; CGM-Daten waren rar und meist unverändert.
Fragestellung
Welche glykämischen Outcomes zeigen Jugendliche mit CFRD, insbesondere unter CFTR-Modulatoren und Diabetestechnologien?
Methode
Systematische Übersicht nach PRISMA; Registereintrag in PROSPERO (CRD420251268343); Suche in PubMed, Embase, Scopus, Web of Science und CENTRAL von Januar 2000 bis November 2025.
Ergebnisse
1.920 Datensätze identifiziert, 1.609 gescreent, 25 Volltexte beurteilt, 10 Studien eingeschlossen. Evidenz vor allem aus kleinen Beobachtungskohorten mit großer Heterogenität; zu CGM und Diabetestechnologien war die Evidenz begrenzt.
Einschränkungen
Vor allem kleine Beobachtungskohorten; deutliche Heterogenität; CGM-Daten selten und uneinheitlich berichtet.
Schlussfolgerung der Autor:innen
Die Evidenz zu glykämischen Outcomes bei Jugendlichen mit CFRD ist begrenzt. Für CFTR-Modulatoren und reale Glukosemuster besteht weiterhin Evidenzbedarf, besonders in pädiatrischen Studien.
Kernaussagen
- Nur 10 eingeschlossene Studien zur CFRD im Jugendalter
- HbA1c unter CFTR-Modulatoren mit heterogenen Effekten
- CGM-Daten waren selten und meist unverändert
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Hormone Research in Paediatrics, online erschienen am 04.11.2026. Verfasst von W Roesler-Wilhelm und 4 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Cystic fibrosis–related diabetes (CFRD) is the most common endocrine complication of cystic fibrosis. In the era of CFTR modulators and advanced diabetes technologies, their impact on glycemic outcomes in youth remains unclear.
Objectives
To systematically synthesize glycemic outcomes in youth with CFRD, focusing on the effects of CFTR modulators and diabetes technologies.
Methods
This systematic review followed PRISMA guidance and was registered in PROSPERO (CRD420251268343). PubMed, Embase, Scopus, Web of Science, and CENTRAL were searched (January 2000–November 2025). Eligible studies included individuals <30 years with CFRD reporting any glycemic outcomes. Studies were classified as CORE 1 (strict pediatric CFRD criteria) or CORE 2 (supportive evidence from mixed-age populations).
Results
Of 1,920 records identified, 1,609 were screened after duplicate removal. Full-text assessment of 25 studies resulted in 10 included studies (table 1). Evidence was derived mainly from small observational cohorts with substantial heterogeneity. Across CORE 1 studies, CFTR modulators showed heterogeneous effects on HbA1c. CGM data were scarce and inconsistently reported, limiting the ability to detect true effects. Among studies reporting CGM outcomes, metrics were generally unchanged, including stable variability, suggesting a discordance between HbA1c and real-time glycemic patterns. Evidence on diabetes technologies in CFRD populations <30 years was limited. Mixed-age cohorts demonstrated improvements with automated insulin delivery (TIR:∼60%→76%; CV: ∼39%→30%).
Conclusions
Evidence on glycemic outcomes in youth with CFRD is limited, with only a small number of pediatric-focused studies and scarce CGM data. Available findings suggest variable changes in HbA1c and insufficient evidence to determine the impact of CFTR modulators on real-time glycemic patterns, highlighting evidence gaps and the need for pediatric-focused studies.
Zitieren
APA
Roesler-Wilhelm, W., Coimbra, L., Zorron, M., Chobot, A., & Santos, T. J. D. (2026). P-222: Glycemic outcomes in cystic fibrosis–related diabetes in youth: discordance between HbA1c and CGM metrics and limited evidence on diabetes technologies — a systematic review. Hormone Research in Paediatrics, 99(Supplement_4). https://doi.org/10.1159/hrp/adaag020.280
Vancouver
Roesler-Wilhelm W, Coimbra L, Zorron M, Chobot A, Santos TJD. P-222: Glycemic outcomes in cystic fibrosis–related diabetes in youth: discordance between HbA1c and CGM metrics and limited evidence on diabetes technologies — a systematic review. Hormone Research in Paediatrics. 2026;99(Supplement_4). doi:10.1159/hrp/adaag020.280
BibTeX
@article{RoeslerWilhelm2026,
author = {Roesler-Wilhelm, W and Coimbra, L and Zorron, M and Chobot, A and Santos, T Jeronimo dos},
title = {P-222: Glycemic outcomes in cystic fibrosis–related diabetes in youth: discordance between HbA1c and CGM metrics and limited evidence on diabetes technologies — a systematic review},
journal = {Hormone Research in Paediatrics},
year = {2026},
volume = {99},
number = {Supplement_4},
doi = {10.1159/hrp/adaag020.280}
}
EUVIMED